Paper Details

  1. Home
  2. Paper Details

Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.

Author: ChenDewang, JiangJie, LiuXiaoping, LuoSong, MaZeren, WangJia, XuXiaosheng, ZhouJian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Ankylosing spondylitis (AS) is a chronic inflammatory condition affecting the spine and sacroiliac joints. Five TNF-alpha inhibitors are used to treat AS, but the safety of these medications for AS is not entirely clear.
Paper Details　
Original Abstract of the Article :
Ankylosing spondylitis (AS) is a chronic immune-mediated disease affecting the sacroiliac joints and the spine, manifesting with new bone formation and osteopenia. Five tumor necrosis factor-alpha (TNF-α) inhibitors (infliximab, etanercept, adalimumab, certolizumab, and golimumab) are available for ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484196/

データ提供：米国国立医学図書館（NLM）

Safety of TNF-α Inhibitors in Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory disease that can affect the spine and sacroiliac joints, causing significant pain and stiffness. Like a relentless desert wind that slowly erodes the landscape, AS can gradually lead to debilitating symptoms. This study embarks on a meta-analysis of the safety of TNF-α inhibitors, a class of drugs used to treat AS. The researchers aim to navigate the complex terrain of drug safety and provide a comprehensive overview of the available evidence.

Evaluating the Safety of TNF-α Inhibitors

The study reviews the safety data from five TNF-α inhibitors used to treat AS. The analysis aims to assess the potential risks associated with these drugs, much like an experienced traveler carefully evaluating the dangers of a desert crossing. This comprehensive assessment is crucial for guiding treatment decisions and ensuring patient safety.

Navigating the Risks and Benefits

The study highlights the importance of carefully evaluating the risks and benefits of TNF-α inhibitors in treating AS. While these drugs can effectively alleviate symptoms, they can also carry potential side effects. A thorough understanding of these risks, akin to recognizing the warning signs in a desert environment, is essential for making informed treatment decisions.

Dr. Camel's Conclusion

This meta-analysis serves as a valuable compass for navigating the complex landscape of TNF-α inhibitor safety in ankylosing spondylitis. By carefully evaluating the risks and benefits, both patients and healthcare providers can make informed decisions about treatment options, ensuring the best possible outcomes in the long-term management of this challenging disease.

Date :
  1. Date Completed 2017-07-17
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

28640088

DOI: Digital Object Identifier

PMC5484196

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.